ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone and Men's Health Articles
Selling Testosterone: Review of the American Market
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="CoastWatcher" data-source="post: 88284" data-attributes="member: 2624"><p>In the United States, testosterone replacement therapy is approved by the FDA for treatment of classical hypogonadism. Off-label indications have resulted in a dramatic expansion in prescriptions in the American market. It is the belief of many that marketing - to potential patient and doctor are impacting prescriber behavior. PubMed, Embase, and Scopus were searched up to July 2017 for all relevant publications reporting on assessments of the TRT market size, economic costs associated with hypogonadism, trends in TRT prescriptions, drug discontinuation rates, and advertising and sales efforts in the USA.</p><p></p><ul> <li data-xf-list-type="ul">PubMed, Embase, and Scopus were searched up to July 2017 for all relevant publications reporting on assessments of the TRT market size, economic costs associated with hypogonadism, trends in TRT prescriptions, drug discontinuation rates, and advertising and sales efforts in the USA.</li> <li data-xf-list-type="ul">Twenty retrospective studies were included in the final analysis.</li> <li data-xf-list-type="ul">The market size for hypogonadism constitutes 5.6–76.8% of men in the USA, with the lower end of the range representing the strictest criteria for diagnosis.</li> <li data-xf-list-type="ul">Men with a diagnosis of hypogonadism consume $14,118 in direct and indirect costs to the payer.</li> <li data-xf-list-type="ul">Over the last 2 decades, TRT prescriptions have increased between 1.8- and 4-fold.</li> <li data-xf-list-type="ul"><strong>A minority of patients undergo PSA and hematocrit testing, with 10–26.6% of men not having undergone serum testosterone testing at all prior to initiating therapy.</strong></li> <li data-xf-list-type="ul"><strong>After one year, 80–85% of men discontinue TRT. </strong></li> <li data-xf-list-type="ul">There is an association between direct-to-consumer advertising and testosterone testing, TRT prescriptions, and TRT without testosterone testing.</li> <li data-xf-list-type="ul">There is a high prevalence of misinformation on Internet advertising.</li> </ul><p></p><p></p><p>"Marketing and Testosterone Treatment in the USA: A Systematic Review," <em>European Urology, 2017 10/16, </em><a href="http://www.eu-focus.europeanurology.com/article/S2405-4569(17)30256-0/fulltext" target="_blank">http://www.eu-focus.europeanurology.com/article/S2405-4569(17)30256-0/fulltext</a></p></blockquote><p></p>
[QUOTE="CoastWatcher, post: 88284, member: 2624"] In the United States, testosterone replacement therapy is approved by the FDA for treatment of classical hypogonadism. Off-label indications have resulted in a dramatic expansion in prescriptions in the American market. It is the belief of many that marketing - to potential patient and doctor are impacting prescriber behavior. PubMed, Embase, and Scopus were searched up to July 2017 for all relevant publications reporting on assessments of the TRT market size, economic costs associated with hypogonadism, trends in TRT prescriptions, drug discontinuation rates, and advertising and sales efforts in the USA. [LIST] [*]PubMed, Embase, and Scopus were searched up to July 2017 for all relevant publications reporting on assessments of the TRT market size, economic costs associated with hypogonadism, trends in TRT prescriptions, drug discontinuation rates, and advertising and sales efforts in the USA. [*]Twenty retrospective studies were included in the final analysis. [*]The market size for hypogonadism constitutes 5.6–76.8% of men in the USA, with the lower end of the range representing the strictest criteria for diagnosis. [*]Men with a diagnosis of hypogonadism consume $14,118 in direct and indirect costs to the payer. [*]Over the last 2 decades, TRT prescriptions have increased between 1.8- and 4-fold. [*][B]A minority of patients undergo PSA and hematocrit testing, with 10–26.6% of men not having undergone serum testosterone testing at all prior to initiating therapy.[/B] [*][B]After one year, 80–85% of men discontinue TRT. [/B] [*]There is an association between direct-to-consumer advertising and testosterone testing, TRT prescriptions, and TRT without testosterone testing. [*]There is a high prevalence of misinformation on Internet advertising. [/LIST] "Marketing and Testosterone Treatment in the USA: A Systematic Review," [I]European Urology, 2017 10/16, [/I][URL]http://www.eu-focus.europeanurology.com/article/S2405-4569(17)30256-0/fulltext[/URL] [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone and Men's Health Articles
Selling Testosterone: Review of the American Market
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top